STOCK TITAN

Soligenix Inc - SNGX STOCK NEWS

Welcome to our dedicated page for Soligenix news (Ticker: SNGX), a resource for investors and traders seeking the latest updates and insights on Soligenix stock.

Overview

Soligenix Inc (SNGX) is a late-stage biopharmaceutical company based in the United States that specializes in developing and commercializing innovative products addressing unmet medical needs. With a focus on orphan diseases, inflammation, oncology, and biodefense, the company leverages advanced technologies to create therapeutics and vaccine candidates designed for rare and niche medical conditions.

Business Segments and Product Portfolio

Soligenix operates two distinct business segments:

  • Specialized BioTherapeutics: This segment is dedicated to developing novel therapies for rare disorders and orphan diseases. Among its flagship programs is a photodynamic therapy that employs synthetic hypericin for the treatment of cutaneous T-cell lymphoma (CTCL). The company utilizes safe, visible light activation to trigger the therapeutic effects of its compounds, thereby reducing the risks associated with traditional treatments.
  • Public Health Solutions: Focused on biodefense and vaccine development, this segment includes programs to develop vaccines for ricin toxin exposure, filovirus infections such as those caused by Ebola and Marburg viruses, and other emerging infectious diseases. The development of thermostabilized vaccine formulations via its proprietary technology platform enhances their resilience and accessibility even in challenging storage environments.

Innovative Therapeutic Approaches

At its core, Soligenix is an innovator in biopharmaceutical research. The company’s approach emphasizes:

  • Orphan Drug Focus: Addressing diseases with significant unmet medical needs, ensuring that even rare conditions receive the focus required for treatment breakthroughs.
  • Advanced Photodynamic Therapy: Through programs such as HyBryte, Soligenix demonstrates the effective use of synthetic hypericin combined with visible light activation. This method offers a potent, targeted treatment for CTCL, minimizing systemic exposure and potential side effects inherent in conventional treatments.
  • Heat-Stabilized Vaccine Platforms: Utilizing a unique combination of GRAS excipients and lyophilization, the company manufactures vaccines that are stable at ambient temperatures, a critical factor for both military and civilian biodefense applications.

Market Position and Competitive Landscape

Operating within a highly specialized niche, Soligenix distinguishes itself with its dual focus on orphan therapeutics and biodefense. The company continues to advance clinical trials with clear protocols and has secured orphan drug and fast track designations from prominent regulatory authorities. By leveraging government grants and non-dilutive funding, Soligenix is well positioned to overcome the challenges associated with clinical validation and commercialization in competitive markets.

Intellectual Property and Strategic Collaborations

Soligenix has built a robust intellectual property portfolio that encompasses novel synthesis methods and treatments for rare diseases. Strategic manufacturing collaborations further enhance its capabilities in scaling production and ensuring quality, critical factors for commercial success. These alliances help solidify its market role and support ongoing research, clinical trials, and regulatory activities.

Commitment to Unmet Medical Needs

The company is unwavering in its commitment to provide therapies where options are limited. Whether it is through innovative photodynamic treatment for CTCL or next-generation vaccine platforms aimed at biodefense, Soligenix prioritizes technological advancement and patient safety. The detailed clinical trial programs and continuous research efforts underscore its expertise and dedication within the biopharmaceutical field.

Conclusion

In summary, Soligenix Inc establishes its significance through a combination of advanced scientific methodologies and a focused strategy on rare diseases with high unmet needs. Its dual business segments not only contribute to a diversified product pipeline but also reinforce its authorization as a relevant player in the competitive biopharmaceutical landscape. Investors and industry experts can view Soligenix as a company that merges solid clinical data with a strategic vision for addressing health challenges that many others overlook.

Rhea-AI Summary

Soligenix, Inc. (Nasdaq: SNGX) reported its financial results for Q1 2022, with revenues of $0.2 million, up from $0.1 million in Q1 2021. The company incurred a net loss of $4.3 million, increasing from $2.4 million in the previous year. Key upcoming milestones include submitting a New Drug Application for HyBryte™ for cutaneous T-cell lymphoma and initiating a Phase 2a trial for SGX302 in psoriasis. With $22.9 million in cash and government funding support, Soligenix is positioned to advance its product development strategies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.98%
Tags
-
Rhea-AI Summary

Soligenix, Inc. (Nasdaq: SNGX) announced it has secured approximately $1.4 million in non-dilutive funding through government tax programs. This includes $1.2 million from New Jersey's Technology Business Tax Certificate Transfer Program and $0.2 million from the UK's HMRC R&D Tax Credit Program. Over the past twelve years, Soligenix has received about $7.6 million in non-dilutive funding, supporting its rare disease pipeline. They plan to file a new drug application for HyBryte™, treating cutaneous T-cell lymphoma, later this year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.43%
Tags
none
-
Rhea-AI Summary

Soligenix, Inc. (SNGX) reported its financial results for the year ended December 31, 2021, revealing revenues of $0.8 million, down from $2.4 million in 2020. The net loss decreased to $12.6 million ($0.31 per share) from $17.7 million ($0.64 per share) in 2020. Key developments include plans to submit an NDA for HyBryte™ for cutaneous T-cell lymphoma and initiate a Phase 2a trial for SGX302 in psoriasis. Cash reserves stood at $23.3 million, sufficient to support upcoming milestones. The company remains open to strategic partnerships and acquisitions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.39%
Tags
Rhea-AI Summary

Soligenix, Inc. (Nasdaq: SNGX) announced positive results from a study of its CiVax™ COVID-19 booster vaccine in non-human primates. Administered seven months post-primary vaccination, the booster rapidly enhanced neutralizing antibody responses against the Delta and Omicron variants. Antibody levels increased by up to 27-fold within a week and 243-fold within three weeks. CiVax™, supported by a $1.5M SBIR grant from NIAID, showcases broad potential due to its heat-stable formulation, which could simplify global vaccination logistics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.45%
Tags
covid-19
-
Rhea-AI Summary

SG Blocks is leading the seed round investment in Moliving, a luxury nomadic hospitality solution, to enhance modular living and hospitality. The funds will support the construction of 60 units for Moliving's flagship hotel in Hudson Valley, with potential for 400 additional units through five planned locations in 2023. This collaboration highlights the synergy between SG Blocks and Moliving, as both aim to meet market demands sustainably. The flagship hotel, Moliving at Hurley House, is set to open in Summer 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.94%
Tags
none
-
Rhea-AI Summary

Soligenix, Inc. (Nasdaq: SNGX) has announced that Jonathan Guarino, CFO, will present at the Q1 Virtual Investor Summit on March 8, 2022, at 1:15 PM EST. The summit runs from March 8-9 and features one-on-one meetings and company presentations. Attendees can access the presentation through the event platform. Soligenix focuses on treating rare diseases, with products like HyBryte™ for cutaneous T-cell lymphoma and vaccine candidates for various infectious diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.94%
Tags
conferences
Rhea-AI Summary

Soligenix, a late-stage biopharmaceutical company focused on rare diseases, will present at the BIO CEO & Investor Conference from February 14-17, 2022. The presentation, available on-demand from February 11, will be led by CEO Christopher J. Schaber, PhD. Attendees can also schedule one-on-one meetings with management during the conference. Soligenix is advancing potential treatments like HyBryte™ for cutaneous T-cell lymphoma and RiVax® for ricin toxin exposure. For more details, visit the conference website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

Soligenix (SNGX) provided an update on its strategic plans and development pipeline in a letter from CEO Dr. Christopher J. Schaber. Key upcoming milestones include submitting an NDA for HyBryte™ in treating cutaneous T-cell lymphoma (CTCL) and initiating a Phase 2 trial for SGX302 in psoriasis. HyBryte™ shows potential peak U.S. sales exceeding $90 million, with a global psoriasis market opportunity over $1 billion. Additionally, ongoing development of vaccines and the significance of a $20 million partnership with Pontifax were highlighted, ensuring sufficient capital into 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.9%
Tags
none
-
Rhea-AI Summary

Soligenix (Nasdaq: SNGX), a late-stage biopharmaceutical company, announced its participation in two upcoming virtual investor conferences. The H.C. Wainwright BioConnect Conference will take place from January 10-13, 2022, with an on-demand presentation available starting January 10 at 7 AM ET. The Biotech Showcase will be held from January 10-12 and 17-19, 2022, with presentations for registered attendees commencing on January 10. Soligenix's management will also conduct one-on-one meetings throughout both conferences.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.9%
Tags
conferences
Rhea-AI Summary

Soligenix, Inc. (Nasdaq: SNGX) announced that dusquetide shows significant efficacy in reducing tumor size in nonclinical models, reinforcing previous studies. It was effective both as a standalone therapy and in combination with radiation and chemotherapy for the MCF-7 breast cancer cell line. Dusquetide has also shown positive results in reducing severe oral mucositis, leading to enhanced survival rates. The company is exploring further product opportunities in oncology, motivated by strong Phase 2 and 3 study data. Dusquetide holds Fast Track Designation for treating oral mucositis, with a robust intellectual property portfolio backing its development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.8%
Tags
none

FAQ

What is the current stock price of Soligenix (SNGX)?

The current stock price of Soligenix (SNGX) is $2.21 as of April 1, 2025.

What is the market cap of Soligenix (SNGX)?

The market cap of Soligenix (SNGX) is approximately 7.0M.

What is the core focus of Soligenix Inc?

Soligenix Inc is focused on developing and commercializing innovative therapeutics and vaccines targeting rare diseases with significant unmet medical needs, particularly in oncology, inflammation, and biodefense.

How does Soligenix generate revenue?

The company primarily generates revenue through government contracts, grants, and milestone-based funding tied to its clinical trial successes and ongoing development programs within its specialized and public health segments.

What are the main business segments of Soligenix?

Soligenix operates two main segments: Specialized BioTherapeutics, which develops treatments for orphan diseases such as CTCL, and Public Health Solutions, which focuses on biodefense-related vaccine development.

What therapeutic areas does Soligenix focus on?

The company targets multiple therapeutic areas including cutaneous T-cell lymphoma (CTCL), orphan diseases, inflammatory conditions, and biodefense, with products designed to address both clinical and public health challenges.

How does HyBryte™ differentiate itself in treating CTCL?

HyBryte™ employs a novel photodynamic therapy using synthetic hypericin activated by safe, visible light, offering targeted treatment with minimal systemic exposure and a favorable safety profile compared to traditional therapies.

What role does intellectual property play for Soligenix?

Soligenix has established a robust portfolio of patents covering novel synthesis methods and therapeutic applications, which strengthens its competitive position and supports its advanced clinical programs.

How is the company supported financially?

Soligenix benefits from government grants, non-dilutive funding, and strategic partnerships, allowing it to progress in clinical trials and product development while mitigating financial risk.

What are the key technologies used in Soligenix's vaccine programs?

The company uses a proprietary heat stabilization platform, ThermoVax®, which employs GRAS excipients and lyophilization to produce vaccines that are stable at ambient temperatures, enhancing their practical use in biodefense.
Soligenix Inc

Nasdaq:SNGX

SNGX Rankings

SNGX Stock Data

6.97M
2.51M
0.03%
1.22%
4.01%
Biotechnology
Pharmaceutical Preparations
Link
United States
PRINCETON